ES2106855T3 - Analogos de 3-benciliden-1-carbamoil-2-pirrolidona. - Google Patents

Analogos de 3-benciliden-1-carbamoil-2-pirrolidona.

Info

Publication number
ES2106855T3
ES2106855T3 ES92902746T ES92902746T ES2106855T3 ES 2106855 T3 ES2106855 T3 ES 2106855T3 ES 92902746 T ES92902746 T ES 92902746T ES 92902746 T ES92902746 T ES 92902746T ES 2106855 T3 ES2106855 T3 ES 2106855T3
Authority
ES
Spain
Prior art keywords
unsubstituted
represent
carbamoil
represents hydrogen
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92902746T
Other languages
English (en)
Inventor
Susumu Kamata
Takeshi Shiota
Nobuhiro Haga
Toshihiko Okada
Hirokuni Jyoyama
Saichi Matsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2106855T3 publication Critical patent/ES2106855T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/40—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE PRESENTA UN NUEVO ANALOGO DE LA 3-BENZILIDENO-1-CARBAMOIL-2PIRROLIDINA REPRESENTADO POR LA FORMULA (I), QUE TIENE EXCELENTES PROPIEDADES ANTIINFLAMATORIAS Y MAS PARTICULARMENTE ES UTIL PARA EL TRATAMIENTO DE LA INFLAMACION CRONICA SIN PROVOCAR EFECTOS ADVERSOS TALES COMO GASTRITIS, EN DONDE R1 Y R2 REPRESENTAN CADA UNA INDEPENDIENTEMENTE HIDROGENO, ALQUIL, ALCOXIDO O HALOGENO, R3 REPRESENTA HIDROGENO O ACIL; R4 REPRESENTA HIDROGENO, ALQUIL, HIDROXIDO, ALCOXIDO, CIANO O HALOGENO; R5 Y R6 REPRESENTAN CADA UNA INDEPENDIENTEMENTE HIDROGENO, ALQUIL, ARIL, ARALQUIL, ETEROCICLO, AMINO SUBSTITUIDO O INSUBSTITUIDO O OR7 EN DONDE R7 REPRESENTA HIDROGENO, ALQUIL, ARIL, ACIL O ARALQUIL, O ALTERNATIVAMENTE R5 Y R6 SE COMBINAN JUNTAS CON EL ATOMO DE NITROGENO PARA FORMAR UN GRUPO HETEROCICLICO Y PUEDE ADEMAS CONTENER N, O Y /O S; Y X E Y REPRESENTAN CADA UNA INDEPENDIENTEMENTE O, S, IMINO SUBSTITUIDO O INSUBSTITUIDO O METILENO SUBSTITUIDO O INSUBSTITUIDO.
ES92902746T 1991-01-21 1992-01-14 Analogos de 3-benciliden-1-carbamoil-2-pirrolidona. Expired - Lifetime ES2106855T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2161891 1991-01-21

Publications (1)

Publication Number Publication Date
ES2106855T3 true ES2106855T3 (es) 1997-11-16

Family

ID=12060040

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92902746T Expired - Lifetime ES2106855T3 (es) 1991-01-21 1992-01-14 Analogos de 3-benciliden-1-carbamoil-2-pirrolidona.

Country Status (12)

Country Link
US (2) US5319099A (es)
EP (1) EP0525197B1 (es)
JP (1) JP3108097B2 (es)
KR (1) KR0133550B1 (es)
AT (1) ATE157355T1 (es)
AU (1) AU646722B2 (es)
CA (1) CA2078790C (es)
DE (1) DE69221794T2 (es)
ES (1) ES2106855T3 (es)
HU (1) HU214333B (es)
NO (1) NO179142C (es)
WO (1) WO1992012966A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0595546T3 (da) * 1992-10-28 1996-04-15 Shionogi & Co Benzylidenderivater
JP3507124B2 (ja) * 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
JP3507138B2 (ja) 1994-07-15 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造方法
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6281229B1 (en) * 1997-06-27 2001-08-28 Kaneka Corporation Heat shock factor activity inhibitors
DE1041982T1 (de) * 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTEN HETEROCYCLISCHEN HARNSTOFFEN
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ES2155817T3 (es) * 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7351834B1 (en) * 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000041698A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003009815A2 (en) 2001-07-25 2003-02-06 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
ES2393900T3 (es) * 2001-12-03 2012-12-28 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
DK1580188T3 (da) * 2002-02-11 2012-02-06 Bayer Healthcare Llc Forbindelser af arylurea som kinaseinhibitorer
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
AU2003210969A1 (en) * 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
CN1856469B (zh) * 2003-07-23 2013-03-06 拜耳医药保健有限责任公司 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
KR20100017184A (ko) * 2007-04-20 2010-02-16 데시페라 파마슈티칼스, 엘엘씨. 골수증식성 질환 및 다른 증식성 질환의 치료에 유용한 키나제 억제제
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
EA201170627A1 (ru) * 2008-10-29 2011-10-31 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
MX2011004903A (es) * 2008-11-10 2011-05-30 Pfizer Ltd Pirrolidinas.
DK2398500T3 (da) 2009-02-20 2019-05-13 2 Bbb Medicines B V Glutathion-baseret lægemiddelafgivelsessystem
SG175896A1 (en) 2009-05-06 2011-12-29 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2018039244A1 (en) * 2016-08-22 2018-03-01 North Carolina State University 5-benzylidene-4-oxazolidinones
EP3746060A1 (en) 2018-01-31 2020-12-09 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
US12509456B2 (en) 2019-03-11 2025-12-30 Deciphera Pharmaceuticals, Llc Solid state forms of ripretinib
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
RS66335B1 (sr) 2019-12-30 2025-01-31 Deciphera Pharmaceuticals Llc Kompozicije 1-(4-bromo-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
DK4181387T3 (da) 2021-11-15 2025-03-31 Siemens Schweiz Ag Halvtrins-motordrivenhed
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1472789A1 (de) * 1965-12-10 1969-01-23 Agfa Gevaert Ag Gelbe Lichthofschutz- und Filterfarbstoffe fuer photographische Materialien
US3624081A (en) * 1967-02-15 1971-11-30 Sterling Drug Inc 1-acyl-2-ethylidenepyrrol-idine-3-carboxamides
DE1932827C3 (de) * 1969-06-28 1978-10-05 Bayer Ag, 5090 Leverkusen Cycloaliphatische Imidazolidin-2-on-1-carbonsäure-amide, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Herbizide
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
DE2658905A1 (de) * 1976-12-24 1978-10-19 Bayer Ag Beta-lactam-antibiotica, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS5879944A (ja) * 1981-11-09 1983-05-13 Kanegafuchi Chem Ind Co Ltd ３，５−ジ・タ−シヤリ−・ブチルスチレン誘導体及び抗炎症、鎮痛、解熱剤並びに血小板凝集阻害剤
JPH0623194B2 (ja) * 1985-03-23 1994-03-30 鐘淵化学工業株式会社 新規ラクタム誘導体及び抗炎症剤
JPH066571B2 (ja) * 1985-05-09 1994-01-26 エーザイ株式会社 ２−ピロリドン誘導体
JPS6229570A (ja) * 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US5191084A (en) * 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents

Also Published As

Publication number Publication date
KR927003540A (ko) 1992-12-18
DE69221794T2 (de) 1998-03-19
US5319099A (en) 1994-06-07
DE69221794D1 (de) 1997-10-02
NO179142C (no) 1996-08-14
HU9203304D0 (en) 1992-12-28
AU646722B2 (en) 1994-03-03
CA2078790A1 (en) 1992-07-22
EP0525197B1 (en) 1997-08-27
ATE157355T1 (de) 1997-09-15
US5319100A (en) 1994-06-07
HUT65618A (en) 1994-07-28
CA2078790C (en) 1998-10-06
HU214333B (hu) 1998-03-02
KR0133550B1 (ko) 1998-04-23
NO923528D0 (no) 1992-09-11
WO1992012966A1 (en) 1992-08-06
JP3108097B2 (ja) 2000-11-13
NO923528L (no) 1992-11-12
EP0525197A1 (en) 1993-02-03
EP0525197A4 (en) 1993-04-07
NO179142B (no) 1996-05-06
AU1163492A (en) 1992-08-27

Similar Documents

Publication Publication Date Title
ES2106855T3 (es) Analogos de 3-benciliden-1-carbamoil-2-pirrolidona.
CO4950558A1 (es) Moduladores de receptores de aminoacidos excitadores
AR003937A1 (es) Compuesto ciclico que tiene efecto antagonico al receptor de taquiquinina, proceso para producirlo y composicion farmaceutica que lo contiene.
AR011913A1 (es) Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
UA26427A (uk) Похідhі ксаhтиhу у вигляді суміші ізомерів або іhдивідуальhих ізомерів, що мають властивість аhтагоhіста адеhозиhу
ES2161231T3 (es) Compuestos heterociclicos como antagonistas de bradiquinina.
ES2164072T3 (es) Heterociclos no aromaticos que contienen nitrogeno sustituidos con bencilamino.
DK1221440T3 (da) Benzoheterocykliske derivater der er nyttige som vasopressin- eller oxytocinmodulatorer
GT199900119A (es) Jarabe antihistaminico estabilizado.
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
UA39099C2 (uk) Циклічні азотовмісні похідні, суміш їх ізомерів або окремі ізомери, або їх солі
ES2055056T3 (es) Derivados de pirimidopirimidina.
ES2067500T3 (es) 1-indolilalquil-4-(piridinil-sustituidas)piperazinas.
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
ES2061845T3 (es) Un procedimiento para preparar un compuesto espiro.
ES2126097T3 (es) Derivados de diesteres fosfonicos.
DK0625164T3 (da) Cykliske forbindelser, der er nyttige som inhibitorer af blodpladeglycoprotein IIb/IIIa
UY24919A1 (es) Compuestos amínicos sustituidos, procedimiento de preparación, y su aplicación
UY24010A1 (es) Nuevos pirrolocarbazoles
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
ES2190422T3 (es) Antagonistas selectivos de receptores de adenosina a2b.
BR0309744A (pt) Ligandos receptores de melanocortina e composição compreendendo os mesmos
ES2060709T3 (es) Derivados de piridilo y pirimidilo.
ES2148858T3 (es) (aminoalquil- y acilaminoalquil-oxi)benciloxiquinolinas, procedimiento para su preparacion y su empleo como antagonistas de receptores de bradiquinina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525197

Country of ref document: ES